In Hong Kong on February 5, 2026, Akeso, Inc. (9926.HK) announced that ivonescimab, a groundbreaking bispecific antibody targeting PD-1 and VEGF, has received its fifth Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE).